4D Molecular Therapeutics
FDMT
111 hedge funds and large institutions have $860M invested in 4D Molecular Therapeutics in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
61% more capital invested
Capital invested by funds: $534M → $860M (+$326M)
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
1% more funds holding
Funds holding: 110 → 111 (+1)
0.42% less ownership
Funds ownership: 99.68% → 99.26% (-0.42%)
32% less call options, than puts
Call options by funds: $3.07M | Put options by funds: $4.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.66M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.2M |
| 3 |
VA
VR Adviser
New York
|
+$5.58M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$4.93M |
| 5 |
Janus Henderson Group
London,
|
+$4.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$8.27M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.5M |
| 3 |
Millennium Management
New York
|
-$4.22M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$3.87M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.54M |
FDMT Hedge Fund Activity: Q4 2023 in Review
111 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2023, worth a combined $860M — up 61% from $534M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FDMT positions and 19 closed out — a net gain of 1 holder — while 43 added to existing stakes and 28 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $8.66M. The largest seller was Deerfield Management, exiting entirely with an estimated $8.27M sold.
- 111 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2023, up from 110 in Q3 2023.
- Funds reported $860M of 4D Molecular Therapeutics stock for Q4 2023, up 61% quarter-over-quarter.
- 20 funds opened new 4D Molecular Therapeutics positions in Q4 2023 and 19 closed out, a net change of +1 holder.
- The largest 4D Molecular Therapeutics buyer in Q4 2023 was Goldman Sachs, an estimated $8.66M added.
- The largest 4D Molecular Therapeutics seller in Q4 2023 was Deerfield Management, an estimated $8.27M sold.
Based on aggregated 13F filings for Q4 2023.